June 30, 2025 — Fast Track Initiative, Inc. (FTI) has completed a follow-on investment in Global Vascular Inc. (President and CEO: Kenta Bito; Headquarters: Tokyo, Japan), a medical device company advancing the BioStealth™ drug-eluting stent (DES) platform. This investment is part of Global Vascular’s Series B financing round, which raised a total of JPY 1 billion.
Global Vascular is developing a proprietary DES specifically engineered for the below-the-knee (BTK) segment—an area with limited treatment options for patients suffering from advanced peripheral arterial disease (PAD). The BioStealth™ platform is engineered to reduce foreign body responses implantation, aiming to improve long-term vessel patency and safety for high-risk PAD patients.
Proceeds from the Series B financing will enable Global Vascular to initiate first-in-human clinical trials in Japan, a key milestone on the path to regulatory approval of its BTK stent delivery system incorporating the BioStealth™ technology. Following successful GLP-compliant preclinical studies completed in 2024, the company is now executing a global clinical, regulatory and commercialization strategy with initial focus on the Japanese market.
FTI’s continued support reflects its commitment to backing transformative medical technologies that address significant unmet needs. As the burden of PAD increases globally, innovative platforms like BioStealth™ represent a critical opportunity to improve vascular intervention outcomes and expand treatment options for underserved patient populations.
About Global Vascular
Global Vascular Co., Ltd. is a Tokyo-based medical device company developing next-generation vascular therapies, including the BioStealth™ drug-eluting stent platform. Focused initially on the below-the-knee (BTK) segment of peripheral arterial disease (PAD), Global Vascular is working to bring its proprietary technology to market through clinical validation and a globally focused regulatory strategy. Backed by leading venture investors and strategic partners, the company is committed to delivering minimally invasive vascular solutions that address critical unmet needs.
About Fast Track Initiative:
Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including therapeutics, diagnostics, digital health, healthcare services, and more. The company provides valuable, hands-on support to its 30+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan.
Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/
Media Contact:
For press inquiries or investor inquiries, please email: message.us@fasttrackinitiative.com
